Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Georges Francois Leclerc
Age
18–90
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women more than 18 years old
breast cancer recently diagnosis (no prior treatment), histologically proven
stade II or III in the "International union against cancer"(UICC) classification
non metastatic patient
Eastern Cooperative Oncology Group (ECOG) 0 or 1
Negativity of estrogen and progesterone receptor of the tumor (\<10%)
Absence of overexpression of HER2 according to the classification Immunohistochemistry (IHC) - score 0 or 1+
Patient having read the information note
written, dated and signed Informed consent
You may not be if
Unresectable breast cancer, bilateral, inflammatory (T4d) or metastatic.
Unbalanced diabetes during PET scans (glucose more or equal to 9 mmol)
Small breast cancer indication with first-conserving surgery
Treated breast cancer history
Pregnancy or breastfeeding
Refusal of the patient for trial participation
Private Person of liberty under supervision or under curators
Inability to submit to medical follow-up testing for social or psychological reasons
No affiliation to a social security scheme or medical state aid or the universal medical coverage
Known allergy or hypersensitivity to 18F-fluorodeoxyglucose
Patients with known renal impairment (creatinine clearance \<60 ml / min / 1.73m2) or a known hepatic failure
Patients with a strict regime without salt (sodium levels may be higher than 1 mmol in a dose of 18 FDG).
Clareo Health | Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET
